Forkhead box D1 promotes invasion and metastasis of pancreatic cancer via extracellular signal-regulated kinase pathway

doi:10.16139/j.1007-9610.2020.06.009

Abstract

Abstract:

Objective To study on the expression of forkhead box D1 (FOXD1) in pancreatic cancer and the mechanism of invasion and metastasis of pancreatic cancer through FOXD1 via the extracellular signal-regulated kinase (ERK) pathway. Methods We searched the database of expression of FOXD1 in both pancreatic cancer and normal pancreatic tissue from the Cancer Genome Atlas and analyzed the difference in expression of FOXD1. Expression of FOXD1 mRNA in pancreatic tissue of 15 cases with pancreatic cancer was detected using polymerase chain reaction. Expression of FOXD1 in pancreatic cancer cell lines was analyzed using Western Blot. The effect of FOXD1 knockdown on the expression of proteins associated with epithelial mesenchymal transition(EMT) was investigated using Western Blot. The effect of FOXD1 knockdown on the proliferation and invasion of pancreatic cancer cell lines were tested by cell counting kit-8 assay and Transwell assay. Results FOXD1 was highly expressed in pancreatic cancer tissues and cell lines. Knockdown of FOXD1 attenuated the proliferation and invasion of pancreatic cancer cell lines and enhanced expression of EMT associa-ted proteins including epithelial cadherin and ERK while attenuated expression of neuronal cadherin and phosphorylated ERK. Conclusions FOXD1 would be the oncogene of pancreatic cancer by promoting invasion and metastasis of pancrea-tic cancer via ERK pathway.

Key words: Forkhead box D1, Pancreatic cancer, Epithelial-mesenchymal transition, Extracellular signal-regulated kinase pathway

CLC Number:

R735.9

DING Fangmi, LIU Zhendong. Forkhead box D1 promotes invasion and metastasis of pancreatic cancer via extracellular signal-regulated kinase pathway[J]. Journal of Surgery Concepts & Practice, 2020, 25(06): 486-492.

Figures/Tables 9

References 18

[1]	Siegel RL, Miller KD. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34. doi: 10.3322/caac.21551 URL
[2]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. doi: 10.3322/caac.21338 URL
[3]	Pierrou S, Hellqvist M, Samuelsson L, et al. Cloning and characterization of seven human forkhead proteins: bin-ding site specificity and DNA bending[J]. EMBO J, 1994, 13(20):5002-5012. doi: 10.1002/j.1460-2075.1994.tb06827.x pmid: 7957066
[4]	Nakayama S, Soejima K, Yasuda H, et al. FOXD1 expression is associated with poor prognosis in non-small cell lung cancer[J]. Anticancer Res, 2015, 35(1):261-268. pmid: 25550559
[5]	Zhao YF, Zhao JY, Yue H, et al. FOXD1 promotes breast cancer proliferation and chemotherapeutic drug resistance by targeting p27[J]. Biochem Biophys Res Commun, 2015, 456(1):232-237. doi: 10.1016/j.bbrc.2014.11.064 URL
[6]	Li D, Fan S, Yu F, et al. FOXD1 promotes cell growth and metastasis by activation of vimentin in NSCLC[J]. Cell Physiol Biochem, 2018, 51(6):2716-2731. doi: 10.1159/000495962 URL
[7]	Farhan M, Wang H, Gaur U, et al. FOXO signaling pathways as therapeutic targets in cancer[J]. Int J Biol Sci, 2017, 13(7):815-827. doi: 10.7150/ijbs.20052 pmid: 28808415
[8]	Ernstsson S, Pierrou S, Hulander M, et al. Characterization of the human forkhead gene FREAC-4. Evidence for regulation by Wilms' tumor suppressor gene (WT-1) and p53[J]. J Biol Chem, 1996, 271(35):21094-21099. doi: 10.1074/jbc.271.35.21094 pmid: 8702877
[9]	Gao YF, Liu JY, Mao XY, et al. LncRNA FOXD1-AS1 acts as a potential oncogenic biomarker in glioma[J]. CNS Neurosci Ther, 2020, 26(1):66-75. doi: 10.1111/cns.13152 URL
[10]	Song R, Lopez M, Yosypiv IV. Foxd1 is an upstream re-gulator of the renin-angiotensin system during metanephric kidney development[J]. Pediatr Res, 2017, 82(5):855-862. doi: 10.1038/pr.2017.157 URL
[11]	Wu Q, Ma J, Wei J, et al. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway[J]. Mol Oncol, 2020-05-27.[online ahead of print].
[12]	Wang Y, Qiu C, Lu N, et al. FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner[J]. Int J Oncol, 2018, 52(6):2130-2142. doi: 10.3892/ijo.2018.4359 pmid: 29620165
[13]	Pan F, Li M, Chen W. FOXD1 predicts prognosis of co-lorectal cancer patients and promotes colorectal cancer progression via the ERK 1/2 pathway[J]. Am J Transl Res, 2018, 10(5):1522-1530.
[14]	Li CH, Chang YC, Hsiao M, et al. FOXD1 and Gal-3 form a positive regulatory loop to regulate lung cancer aggressiveness[J]. Cancers (Basel), 2019, 11(12):1897-1915. doi: 10.3390/cancers11121897 URL
[15]	Gao YF, Zhu T, Mao XY, et al. Silencing of forkhead box D1 inhibits proliferation and migration in glioma cells[J]. Oncol Rep, 2017, 37(2):1196-1202. doi: 10.3892/or.2017.5344 URL
[16]	Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition[J]. Nat Rev Mol Cell Biol, 2014, 15(3):178-196. doi: 10.1038/nrm3758 URL
[17]	Li X, Dong M, Zhou J, et al. C6orf106 accelerates pancreatic cancer cell invasion and proliferation via activa-ting ERK signaling pathway[J]. Mol Cell Biochem, 2019, 454(1-2):87-95. doi: 10.1007/s11010-018-3455-0 URL
[18]	Qi ZH, Xu HX, Zhang SR, et al. RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling[J]. Int J Oncol, 2018, 52(4):1105-1116.